We recently isolated a proteoglycan form of macrophage colony-stimulating factor (PG-M-CSF) that carries a chondroitin sulfate glycosaminoglycan chain. Here, we examined the interaction of PG-M-CSF with low density lipoprotein (LDL). When LDL preincubated with PG-M-CSF was fractionated by molecular size sieving chromatography, it was eluted earlier than untreated LDL. When LDL was preincubated with chondroitin sulfate-free 85-kD M-CSF instead of PG-M-CSF, the elution profile of LDL remained unchanged, indicating specific interaction between PG-M-CSF and LDL. The level of PG-M-CSF binding in the wells of a plastic microtitration plate precoated with LDL was significant, this binding being completely abolished by pretreatment of PG-M-CSF with chondroitinase AC, which degrades chondroitin sulfate. The addition of exogeneous chondroitin sulfate or apolipoprotein B inhibited the binding of PG-M-CSF to LDL in a dose-dependent manner, indicating that the interaction between PG-M-CSF and LDL was mediated by the binding of the chondroitin sulfate chain of PG-M-CSF to LDL apolipoprotein B. PG-M-CSF was also demonstrated in the arterial wall, and there were increased amounts of PG-M-CSF in atherosclerotic lesions. The in vitro interaction between PG-M-CSF and LDL thus appears to have physiological significance. (J. Clin. Invest.
Introduction
Proteoglycans (PG)' are macromolecules composed of various kinds of glycosaminoglycan (GAG) chains and various kinds of core proteins, whose moieties are covalently bound with each other (1, 2) . Common GAG include heparan sulfate, chondroitin sulfate, dermatan sulfate, and keratan sulfate ( 1, 2) , the core proteins of these being different. The PG are a highly diverse group of macromolecules; in only a limited number has the molecular structure been established (1, 2) .
PG are widely distributed in animal tissues. The increased amounts of certain arterial PG in atherosclerotic aortas and their affinity for low density lipoprotein (LDL) have lead various investigators to suggest that these PG are involved in the atherosclerotic process (3) (4) (5) (6) (7) . Supporting evidence for the involvement of the PG-LDL complex in the atherosclerotic process has been provided by the isolation of this complex from human vascular lesions (8) . Interaction between PG and LDL is thought to be mediated by the binding of anionic GAG chains to the positively charged amino acid of apolipoprotein B (3) (4) (5) (6) (7) . However, previous studies have also indicated that both core proteins and GAG are essential for the formation of these complexes and that the potential of PG to interact with LDL depends on the nature of the core proteins and on the compositions of the GAG (4, 8, 9) . The interaction between PG molecules and LDL is important in the pathogenesis of atherosclerosis, since this interaction may facilitate the trapping of LDL in the arterial wall or cause structural alterations in the LDL protein, alterations that influence the uptake of lipoprotein by the arterial mesenchyma (10) (11) (12) (13) (14) (15) (16) . To date, however, no specific PG molecule involved in LDL binding has been characterized yet. To clarify the precise role of PG in the pathogenesis of atherosclerosis, it is important to identify PG molecules with such functions.
Macrophage colony-stimulating factor (M-CSF), a growth factor for mononuclear phagocytic cells (17), was first identified as a glycoprotein with a molecular mass of 85 kD (18, 19) . A second M-CSF molecule, with a molecular mass of > 200 kD, and which carries chondroitin sulfate GAG, has since been identified by us and others (20, 21) ; this was designated "proteoglycan form of M-CSF" (PG-M-CSF) (22) . Human M-CSF is produced as a 522-amino acid polypeptide preceded by a 32-amino acid signal peptide (19) . The precursor polypeptides are rapidly dimerized via disulfide bonds and translationally glycosylated (19) . Proteolytic cleavage at the residue around 223 produces an M-CSF subunit of 43 kD (19) . The 85-kD M-CSF is a homodimer of the 43-kD subunit (19) . In contrast, proteolytic cleavage occurring at the residue around 400, but not at that around 223, produces a PG-M-CSF-specific subunit with a molecular mass of 150-200 kD (20, 21) . In addition to having a longer carboxyl terminus than the 43-kD subunit, the PG-M-CSF-specific subunit contains a chondroitin sulfate chain on the COOH-terminal portion (21) . It has also been shown that the combination of the PG-M-CSF-specific subunit with the identical subunit or the 43-kD subunit lacking the COOH-terminal structures yielded homodimeric or heterodimeric PG-M-CSF, respectively (22) . Here, we show the capacity of this newly identified PG, i.e., PG-M-CSF, to bind plasma LDL.
Methods
Materials. The 85-kD M-CSF and PG-M-CSF were purified from media conditioned with Chinese hamster ovary cells transfected with human M-CSF cDNA (19, 21, 22 (Fig. 1 a) . Each fraction was also assayed for M-CSF content by ELISA (Fig. 1 b) . LDL-treated 85-kD M-CSF had the same elution position as the 85-kD M-CSF, indicating no specific interaction between 85-kD M-CSF and LDL. On the other hand, PG-M-CSF mixed with LDL was eluted as a broad peak with a later elution time than the untreated PG-M-CSF.
We next examined, using a modified ELISA (22, 24) , the binding of PG-M-CSF to LDL previously adsorbed onto the wells of a plastic microtitration plate. There was no significant binding of PG-M-CSF to wells not coated with LDL (data not shown), and there was no significant binding of the 85-kD M-CSF to wells coated with LDL, while PG-M-CSF exhibited an appreciable capacity to bind LDL (Fig. 2 a) . Pretreating PG-M-CSF with chondroitinase AC, which degrades the chondroitin sulfate chains of PG-M-CSF, completely abolished the binding (Fig. 2 a) . When added to the interaction mixture, various GAG species, including three chondroitin sulfate preparations, inhibited PG-M-CSF binding to the immobilized LDL (Fig. 2  b) . Heparan sulfate also inhibited the binding, but its inhibition was less effective than that of chondroitin sulfate GAG (Fig. 2  b) . As shown in Fig. 2 Our hypothesis, that PG-M-CSF may bind LDL in the arterial wall in vivo, was supported by the detection of PG-M-CSF in the arterial wall (Fig. 3) . The 85-kD M-CSF and PG-M-CSF showed different behavior on DEAE-Sephacel ion-exchange column chromatography (20) (21) (22) . As shown in Fig. 3 a, the purified 85-kD M-CSF (inset) was eluted mainly at 0.2 M NaCl concentration, while the purified PG-M-CSF (inset) was eluted mainly at 0.4 M NaCl concentration. Using this system, we characterized the M-CSF species present in normal human serum and aortic extracts. The majority of serum M-CSF was eluted at 0.2 M NaCl, and there was a faint appearance of M-CSF at 0.4 M NaCl (Fig. 3 b) , indicating that the 85-kD M-CSF was the major M-CSF species in human serum. The extracts of normal aortic tissue contained M-CSF at a concentration of 1.66-+0.42 ng/g tissue (n = 5), and the extracts of atherosclerotic intima contained higher amounts of M-CSF (4.04-+1.14 ng/g tissue, n = 5) than those from the normal region. The difference of the M-CSF amount between normal region and atherosclerotic region was statistically significant at the level of P < 0.002 (Student's t test). The M-CSF species in the extract of normal aorta was eluted at 0.2 M NaCl, and there was also a second peak observed at 0.4 M NaCl, with a 0.5 a trailing shoulder at 0.5 M NaCl (Fig. 3 c) . There was no significant change in the M-CSF elution pattern of atherosclerotic intimal extract compared with that of the normal aorta, but both peaks contained approximately twofold larger amounts of M-CSF than those in the normal aorta (Fig. 3 d) . The first peak at 0.2 M NaCl corresponding to 85-kD M-CSF of atherosclerotic region contained 0.77±0.32 ng M-CSF, which was higher than that of normal region (0.43±0.10 ng) with a statistical significance at the level of P < 0.05. Similarly, the second peak at 0.4 M NaCl corresponding to PG-M-CSF of atherosclerotic region contained 0.66±0.16 ng M-CSF, which was higher than that of normal region (0.34±0.08 ng) with a statistical significance at the level of P < 0.004. These findings indicated that both 85-kD M-CSF and PG-M-CSF were present in the arterial wall and that both types of M-CSF were increased in atherosclerotic lesions.
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Discussion
Evidence for the existence, in vivo, of the LDL-PG complex has been obtained in biochemical and histochemical studies of aortic lesions (8, 10) . The in vitro interaction between LDL and PG extracted from aorta has also been demonstrated in numerous studies (3) (4) (5) (6) (7) . However, many other aspects of this important interaction remain to be investigated. For example, Vijayagopal et al. (4) found that the binding of free GAG chains to LDL was weaker than that of the parental PG, while Mourao et al. (5) showed that removal of the core protein of aortic PG did not affect the interaction of the PG with LDL. The mechanism whereby macrophage uptake of the LDL-PG complex occurs, however, is not clear; one group reported that LDL modified by PG was metabolized via apolipoprotein B receptors ( 16) , while another reported that the complex was metabolized via a scavenger-receptor pathway (25) . These discrepancies could be due to differences in assay conditions or PG preparations. Most of these studies were done with unfractionated or partially fractionated PG extracted from the aorta. In our study, we clearly showed the affinity of PG-M-CSF and LDL ( Figs.  1 and 2 ). To our knowledge, this study represents the first characterization of a specific proteoglycan molecule involved in the binding of LDL. It is possible that the apparent reduction in molecular size of PG-M-CSF preincubated with LDL ( Fig.  1 b) is due to structural alterations in the linear GAG chain induced by LDL binding, since the interaction between PG-M-CSF and LDL is mediated by the binding of PG-M-CSF chondroitin sulfate GAG chains to LDL (Fig. 2, a and b) . However, the underlying mechanism in this phenomenon remains to be determined. In any case, the finding supports the conclusion that PG-M-CSF and LDL interact and form a complex.
Earlier studies have demonstrated the importance of M-CSF in the atherosclerotic process. First, several recent studies have reported the elevated expression of the M-CSF gene in vascular cell components of atherosclerotic lesions, including endothelial cells, monocytes/macrophages, and smooth muscle cells (26) (27) (28) (29) . Our findings presented here, i.e., the presence of PG-M-CSF and the 85-kD M-CSF in the aortic tissue and the increased amounts of these M-CSF in atherosclerotic lesions (Fig. 3, c and d), are in accordance with these observations. Since little PG-M-CSF was present in serum ( Fig. 3 b) , the increment of PG-M-CSF amount in atherosclerotic lesions might reflect the coaccumulation of PG-M-CSF with LDL. Second, it has been reported that the 85-kD M-CSF stimulates lipoprotein lipase secretion from macrophages and that it enhances both the uptake and efflux of cholesterol in human monocyte-derived macrophages (30) . Both PG-M-CSF and the 85-kD M-CSF act on monocytes, as described previously (22); thus, it can reasonably be assumed that PG-M-CSF modulates LDL metabolism in macrophages.
Although the biologically active nature of PG-M-CSF and its binding of LDL suggest that this molecule makes a profound contribution to the atherosclerotic process, this contribution is still speculative. However, our study offers a new opportunity to study the nature of the interaction between PG and LDL and the subsequent metabolism of such complexes in macrophages. 
